Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Plasma Transfusion in Liver Transplantation

This study has been completed.
Information provided by (Responsible Party):
Etablissement Français du Sang Identifier:
First received: October 6, 2005
Last updated: February 14, 2014
Last verified: February 2014
The aim of the study is to compare the clinical efficacy of three types of plasma secured on the viral level either by quarantine or by chemical treatment in patients undergoing liver transplantation.

Condition Intervention Phase
Bleeding in Liver Transplantation
Other: plasma
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Plasma Transfusion in Liver Transplantation : a Randomized, Double Blind, Multicenter Trial of Methylene Blue, Solvent/Detergent and Quarantined Plasma.

Resource links provided by NLM:

Further study details as provided by Etablissement Français du Sang:

Primary Outcome Measures:
  • Volume of transfused plasma during surgery [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • correction of coagulation abnormalities [ Time Frame: 5 years ]
  • immediate and delayed adverse events [ Time Frame: 15 days ]

Estimated Enrollment: 300
Study Start Date: June 2005
Study Completion Date: December 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Quarantined FFP
Quarantined FFP
Other: plasma
transfusion of more than 15 mL/Kg of plasma
Active Comparator: Methylene blue FFP
Methylene blue FFP
Other: plasma
transfusion of more than 15 mL/Kg of plasma
Active Comparator: Solvent detergent FFP
Solvent detergent FFP
Other: plasma
transfusion of more than 15 mL/Kg of plasma

Detailed Description:

Three types of plasma are transfused in bleeding patients undergoing liver transplantation:

  • quarantined plasma,
  • methylene blue treated plasma,
  • solvent/detergent plasma. The main purpose is to show that the volume of methylene blue treated plasma consumed intraoperatively is equivalent to that of the 2 other types of plasma.

In addition, the correction of coagulation abnormalities are studied.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18 yo and above
  • consent is signed,
  • liver transplantation is indicated,
  • plasma is transfused

Exclusion Criteria:

  • multiorgan transplantation (except combined kidney and liver transplantation)
  • allergy to methylene blue.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00235183

Paris, France, 75015
Sponsors and Collaborators
Etablissement Français du Sang
Principal Investigator: Yves Ozier, MD, PhD Hôpital Cochin, Paris, France
Principal Investigator: Emmanuel Samain, MD, PhD hôpital Jean Minjoz, Besançon, France
Principal Investigator: Marie - Christine Gillon, MD Hôpital Paul Brousse, Villejuif, France
Principal Investigator: Loïc Villalon, MD Hôpital Pontchaillou
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Etablissement Français du Sang Identifier: NCT00235183     History of Changes
Other Study ID Numbers: EFS plasma trial
Study First Received: October 6, 2005
Last Updated: February 14, 2014

Keywords provided by Etablissement Français du Sang:
liver transplantation

Additional relevant MeSH terms:
Pathologic Processes
Methylene Blue
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 22, 2017